Correction to: Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib

Int J Clin Oncol. 2019 Sep;24(9):1169. doi: 10.1007/s10147-019-01488-w.

¹ General Medical Research Center, School of Medicine, Fukuoka University, Fukuoka, Japan. ktamura@fukuoka-u.ac.jp.
² Tohoku University, Miyagi, Japan.
³ Nippon Medical School, Tokyo, Japan.
⁴ Division of Pulmonology and Medical Oncology, Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
⁵ Speciality Care Medicine, Medical Division, Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan.
⁶ PMS Division, Statistics Analysis Department 2, EPS Corporation, Tokyo, Japan.
⁷ Post Marketing Surveillance Group, Pharmacovigilance, Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan.
⁸ Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyusyu University, Fukuoka, Japan.

Abstract

The original article can be found online.